Lazard Asset Management’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
Other funds holding PBYI
ACA
Lazard Asset Management's PBYI Position: Q3 2026 in Review
Lazard Asset Management opened a new position in Puma Biotechnology (PBYI) in Q3 2026: 17,215 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #1719 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in PBYI as recently as Q1 2026.
Lazard Asset Management first reported a position in PBYI in Q2 2021 and has held it in 11 quarters since. The position peaked at $354K in Q4 2025. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.
- Lazard Asset Management held 17,215 shares of Puma Biotechnology worth $171K as of Q3 2026.
- Puma Biotechnology was a new Lazard Asset Management position in Q3 2026.
- Puma Biotechnology made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1719 holding.
- Lazard Asset Management first reported a position in Puma Biotechnology in Q2 2021 and has held it in 11 quarters since.
- Lazard Asset Management's Puma Biotechnology position peaked at $354K in Q4 2025.
- 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.